In this month's Clinical Considerations, we look at managing the difficult patient, ways to improve our diagnostic skills and the latest biologic drug approval for psoriasis.
A panel of veteran dermatologists tackled the topic of difficult patients at the 2016 CalDerm Symposium and offered tips for successfully dealing with these patients.
A recent survey asked dermatologists to visually determine whether clinical images of skin conditions were or were not a fungal infection. Results suggest visual inspection might not be enough for accurate diagnoses.
Dr. Mark Lebwohl talks about the FDA's approval of the anti-interleukin-17 receptor monoclonal antibody brodalumab (Siliq, Valeant Pharmaceuticals) for treatment of adults with moderate-to-severe plaque psoriasis.
Two TNF inhibitors have evidence-based efficacy for HS treatment. Two anti-interleukin inhibitors are being evaluated in small studies. Non-biologic therapies can round out an effective treatment plan.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%